Your browser doesn't support javascript.
loading
Show: 20 | 50 | 100
Results 1 - 4 de 4
Filter
1.
Clin Obes ; 10(5): e12383, 2020 Oct.
Article in English | MEDLINE | ID: mdl-32533634

ABSTRACT

Two cases of middle-aged female patients treated by gastric bypass surgery for weight loss presented to our clinic for a follow-up examination 3-6 months after the surgical procedure (a mini gastric bypass and a modified single anastomosis sleeve-ileostomy). In both patients increased ACTH levels and either high serum cortisol or an increased urinary cortisol excretion was apparent and triggered further endocrine testing. Serum cortisol could not be suppressed adequately by 2 and 4 mg dexamethasone in the standardized oral overnight suppression test while midnight salivary cortisol dropped well below the desired cut-off. This led to the hypothesis of an impaired dexamethasone resorption and could be further substantiated by suppression of serum cortisol below the cut-off by an intravenous dexamethasone application. The data presented point to an impairment of enteral synthetic corticosteroid resorption in patients after gastric bypass surgery and could be of importance for individuals in need for immunosuppressive treatment. In view of the growing number of bariatric procedures, pharmacokinetics of corticosteroids and other drugs should be tested in clinical trials.


Subject(s)
Adrenocortical Hyperfunction/metabolism , Dexamethasone/pharmacokinetics , Gastric Bypass/adverse effects , Hydrocortisone/pharmacokinetics , Postoperative Complications/metabolism , Adrenocortical Hyperfunction/etiology , Adult , Female , Humans , Immunosuppression Therapy , Middle Aged , Postoperative Complications/etiology
2.
Arch Intern Med ; 166(2): 231-3, 2006 Jan 23.
Article in English | MEDLINE | ID: mdl-16432094

ABSTRACT

BACKGROUND: Raynaud disease (RD) is a common disorder affecting 3% to 5% of the healthy population, and occurs in more than 90% of patients with connective tissue diseases. The therapeutic options remain limited, particularly in patients with secondary RD due to connective tissue disease. Theoretical considerations lead to the expectation that phosphodiesterase type 5 inhibitors may improve clinical symptoms and digital blood flow in patients with RD. METHODS: We conducted an open-label pilot study in 40 patients with RD, 33 (82%) of whom had secondary and 7 (18%) of whom had primary RD. Digital blood flow was measured by laser-Doppler flowmetry at room temperature and during the cold-exposure test before medical treatment, 1 hour after the initial intake, and after 2 weeks of continuous treatment (10 mg twice a day) with the novel phosphodiesterase type 5 inhibitor vardenafil. Clinical symptoms were recorded by a patient questionnaire and summarized as the Raynaud condition score. RESULTS: Laser-Doppler flowmetry revealed that vardenafil improved digital blood flow in 28 (70%) patients, whereas 12 (30%) did not respond. In individuals responding, digital blood flow significantly increased by a mean +/- SEM of 21.0% +/- 4.9% and 30.0% +/- 5.7% at 1 hour and 2 weeks of treatment at room temperature, respectively, and by 18.8% +/- 4.4% and 35.1% +/- 7.5% at 1 hour and 2 weeks during the cold-exposure test, respectively (P < .01 for all). Consistently, clinical symptoms improved in 27 (68%) of the 40 patients, and the Raynaud condition score declined from a mean +/- SEM of 5.05 +/- 0.38 to 3.54 +/- 0.31 (P < .001). CONCLUSION: Our data indicate that phosphodiesterase type 5 inhibition significantly improves peripheral blood flow and clinical symptoms in a large subset of patients with RD and, thus, may provide a novel therapeutic approach in such individuals.


Subject(s)
Phosphodiesterase Inhibitors/therapeutic use , Raynaud Disease/drug therapy , Raynaud Disease/physiopathology , 3',5'-Cyclic-GMP Phosphodiesterases , Adult , Blood Flow Velocity , Cyclic Nucleotide Phosphodiesterases, Type 5 , Dose-Response Relationship, Drug , Drug Administration Schedule , Female , Follow-Up Studies , Humans , Laser-Doppler Flowmetry , Male , Middle Aged , Patient Satisfaction , Phosphoric Diester Hydrolases , Pilot Projects , Probability , Raynaud Disease/diagnosis , Risk Assessment , Severity of Illness Index , Treatment Outcome
4.
J Am Acad Dermatol ; 50(2): 210-4, 2004 Feb.
Article in English | MEDLINE | ID: mdl-14726874

ABSTRACT

BACKGROUND: Local side effects at the injection sites of low-molecular-weight heparins are rare and can be of immunologic or nonimmunologic origin. Calcinosis cutis is a rare disorder and occurs in various circumstances. In patients with chronic renal failure the risk of pathologic calcifications is raised due to elevated calcium-phosphorus products. OBJECTIVE: Five patients suffering from renal failure developed remarkable cutaneous and subcutaneous nodules or plaques following subcutaneous nadroparin-calcium injections. Our aim was to evaluate the morphology and precipitation factors of these calcifications and to discuss immunological and nonimmunological differential diagnoses. METHODS: Histological examination, spectroscopic analysis, ultrasonography, allergy testing and reexposition testing including non-calcium heparins were performed. RESULTS: Histology using the van Kossa staining technique revealed calcinosis of the dermis and subcutis. Ultrasonography showed focal subcutaneous calcifications. In all patients the calcium-phosphorus products were elevated. CONCLUSION: Clinicians should be aware that patients with renal failure and elevated calcium-phosphorus products may be at risk of developing calcinosis cutis at calcium-containing heparin injection sites. As a consequence, we propose the use of non-calcium heparins in these patients.


Subject(s)
Anticoagulants/administration & dosage , Anticoagulants/adverse effects , Calcinosis/chemically induced , Nadroparin/administration & dosage , Nadroparin/adverse effects , Skin Diseases/chemically induced , Child , Female , Humans , Injections, Subcutaneous , Male , Middle Aged , Renal Insufficiency
SELECTION OF CITATIONS
SEARCH DETAIL